Founded in Q1 of 2019, Logos Capital is a biotechnology-focused hedge fund managed by Arsani William. Based in California, Logos integrates in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare. The firm combines rigorous scientific diligence with statistical modeling of clinical trials to enhance conviction in its investment decisions and achieve uncorrelated market returns. Logos Capital actively seeks investments in biotechnology companies across the US, supporting innovation in medical science and patient care through direct investments in pioneering firms.
Dr. Arsani William serves as the Managing Partner and Chief Investment Officer of Logos Capital, a global life science investment fund specializing in private and public therapeutic innovation. Before founding Logos, Dr. William played a pivotal role at Farallon Capital Management, contributing significantly to the growth of Farallon’s biopharma portfolio. He holds an MD from Harvard Medical School, where he was recognized as a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University. Dr. William currently holds a board position at Design Therapeutics (NASDAQ:DSGN) and serves as a board observer at Odyssey Therapeutics.
Logos Global Management, headquartered in San Francisco, is a hedge fund managing discretionary assets totaling $1,514,948,821, according to their Form ADV dated April 2024. The firm serves 8 clients. In their most recent 13F filing for Q1 2024, Logos Global Management reported managing $1,235,544,487 in 13F securities, with a top 10 holdings concentration of 53.52%. Their largest holding is Sarepta Therapeutics Inc, with 1,200,000 shares held.
